AbbVie, Biogen Pull Zinbryta From Market Amid EMA Warning

Biogen and Abbvie are withdrawing their multiple sclerosis drug Zinbryta from the market worldwide amid reports of inflammatory brain disorders in users.

The EMA announced it is urgently reviewing the drug following seven reports of inflammatory encephalitis and meningoencephalitis in German and Spanish customers. Biogen has also informed the EMA it will halt all ongoing EU clinical studies for the drug.

Biogen will continue to work with regulators and healthcare providers to manage patients taking the drug. Meanwhile, the EMA will reach out to doctors throughout the EU with updates but advised doctors against writing any prescriptions for the drug.